Working with Japanese partners to fast-track antimalarial drug discovery
Paul Willis (MMV), Hayato Urabe (GHIT) and Takaaki Horii (Eisai)
Paul Willis, Hayato Urabe and Takaaki Horii discuss MMV's partnerships with GHIT and Eisai and their role in the race to discover, develop and deliver new life-saving antimalarial drugs.
Accelerating open drug discovery
Dr Kirandeep Samby, MMV Open project leader
Dr Samby discusses MMV’s open drug discovery initiatives in India.
Brazil: the first real-world use of new protocol for P. vivax case management
Representatives of the Brazilian Ministry of Health and Dr Dhelio Pereira, Director of Clinical Research at the Tropical Medicine Research Center of Rondonia (CEPEM) discuss the results of Phase I of TRuST and the next steps
Dr Pereira and the Brazilian Ministry of Health discuss opportunities and challenges associated with the first real-world use of a new protocol for P. vivax case management.
Studying pyronaridine-artesunate: an important addition to the malaria toolbox
Prof. Francine Ntoumi, Executive Director, Congolese Foundation for Medical Research (FCRM), CANTAM Coordinator
Prof. Ntoumi discusses the findings of a real-life study on Pyramax, an artemisinin-based combination therapy.
A compound with the potential to resist drug resistance
Dr Cornelis Winnips, Global Program Clinical Head, and Dr Anne Claire Marrast, Senior Medical Director, Novartis
Two experts discuss a promising combination that has the potential to combat malaria drug resistance.
Nigeria: Expanding seasonal malaria chemoprevention and overcoming challenges posed by COVID-19
Dr Chibuzo Oguoma, Programme Director, Philanthropic Funding SMC Project, Malaria Consortium/Nigeria
Dr Oguoma discusses the expansion of Nigeria's seasonal malaria chemoprevention programme and overcoming challenges related to COVID-19.
Increasing access to preventive malaria treatment in pregnancy
Elaine Roman, Project Director - Transforming IPT for Optimal Pregnancy (TIPTOP)
A promising approach to increase adherence to intermittent preventive treatment in pregnancy has been the delivery of the intervention by trained community health workers.
Pregnancy registries: providing crucial safety information on the use of drugs during pregnancy
Dr Hellen Barsosio, Senior Clinical Research Scientist, KEMRI/CDC/LSTM Collaboration (KCL)
Dr Hellen Barsosio discusses pregnancy registries, including challenges to data collection posed by COVID-19, working with MMV and future plans.
The brilliance of resistance profiling
Prof. David Fidock and Dr Didier Leroy
Prof. David Fidock and Dr Didier Leroy discuss the malaria drug resistance profiling project.
MMVSola : the science of predicting compound power
Dr Stephen Brand
Dr Stephen Brand discusses the MMVSola project.
"The new mathematical model we have developed allows us to predict how combinations may behave in patients before clinical trials"
Dr Nathalie Gobeau
Dr Nathalie Gobeau discusses the use of ACPR28 modelling in investigating antimalarial drug combinations.
"If we could have a single-dose treatment, it would be wonderful in terms of adherence"
Dr Veronica Soto Calle
Dr Veronica Soto Calle discusses the challenges Peru faces in managing malaria, particularly in the context of COVID-19, and some possible solutions.
"The greatest impact was observed in health surveillance assistants"
Dr Michael Kayange
Dr Michael Kayange discusses severe malaria in Malawi and the RASIEC cohort case-control study.
"SMC Alliance was very important in offering a platform for collaboration between all stakeholders during the COVID-19 pandemic crisis"
Dr André-Marie Tchouatieu
Dr André-Marie Tchouatieu discusses SMC and the global effort to eliminate malaria.
"We are taking several steps to ensure the data we collect for the pregnancy registry are robust"
Dr Stephanie Dellicour
Dr Stephanie Dellicour discusses malaria in pregnant women and the malaria pregnancy registry.
"MFT reduces pressure on the use of a single ACT and increases the therapeutic life of multiple ACTs"
Dr Mohamadou Siribié
Dr Mohamadou Siribié discusses the pilot MFT evaluation in Burkina Faso.
"Drug resistance is fascinating because it demonstrates the idea that evolution always wins”
Dr Maëlle Duffey
Dr Maëlle Duffey discusses her work to characterize resistance as part of MMV’s Drug Discovery team.
"If successful, this new antimalarial combination will have an enormous effect on malaria elimination"
Dr Rella Manego
Dr Rella Manego discusses the burden of malaria in Gabon and the Phase IIb study investigating ganaplacide–lumefantrine in children as young as six months old with uncomplicated malaria.
Discovering and developing new antimalarials during a pandemic
Dr Timothy Wells
Dr Timothy Wells discusses MMV’s research and development strategy in 2020 in the context of global health security and antimicrobial resistance.
"COVID-19 has made it clear that a health threat anywhere is a health threat everywhere"
Dr Meera Venkatesan and Dr Lisa Hare
Dr Meera Venkatesan and Dr Lisa Hare discuss USAID President's Malaria Initiative's work and that of others in securing global health supply chains in 2020.
Big impacts seen in Ghana with use of preventive malaria treatment in pregnancy
Dr Keziah L. Malm
Dr Keziah L. Malm, National Malaria Control Program Manager in Ghana, speaks about her country’s experiences in scaling up intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP).
Malaria Day in Americas: Supporting countries to eliminate relapsing malaria
In this video, Elisa Vidal, MMV's Regional Advisor for Latin America talks about her work in supporting countries in the region to eliminate Plasmodium vivax malaria by improving access to a radical cure.
MMV Open stimulating research into neglected and pandemic diseases
Prof. Lyn-Marie Birkholtz
Prof. Lyn-Marie Birkholtz tells us more about her research experience with the Pandemic Response Box.
Optimizing data management to streamline antimalarial research
Dominique Besson tells us more about the processes that MMV has put in place to manage the huge quantities of data generated by its partners
The Malaria Drug Development Catalyst: accelerating R&D for drug combinations
Dr Mukul Jain
Dr Mukul Jain tells us how the Malaria Drug Development Catalyst is helping to find a combination partner for the promising translational candidate MMV253.
"We need to mobilize government funding for severe malaria care"
Prof. Eric Sompwe Mukomena
Prof. Eric Sompwe Mukomena tells us about some of the challenges of severe malaria case management in his country.
"Malaria elimination will not succeed without the inclusion of women who are, or might become, pregnant"
Dr Wiweka Kaszubska
In 2019, MMV laid the foundations for a new initiative – Malaria in Mothers and Babies (MiMBa, meaning ‘pregnancy’ in the Swahili language) – which aims to address the needs of pregnant women and their newborn babies affected by malaria. Dr Wiweka Kaszubska tells us more.
"MMV has changed the way new antimalarial drugs are developed"
Dr Bernhards Ogutu
Dr Bernhards Ogutu tells us about the case management of uncomplicated malaria in Kenya, and the potential value of MFTs.
"Combatting antimalarial drug resistance requires a highly collaborative approach"
Dr Stephanie Williams
Dr Stephanie Williams tells us more about the threat of antimicrobial resistance and what can be done to tackle it.
Next-generation researchers: International Youth Day 2020
International Youth Day 2020: Interview with Tryphosa Mitoko
Tryphosa Mitoko, MMV's Clinical Trial Administrator tells us about her work and aspirations in malaria research on International Youth Day 2020.
"Ensuring a steady supply of SPAQ is crucial"
Dr André-Marie Tchouatieu
Dr André-Marie Tchouatieu tells us about the progress and challenges of implementing SMC, and MMV’s future plans to increase its impact.
5 questions to MMV about protecting vulnerable populations in pandemic times
Medicines for Malaria Venture
The organization Every Woman Every Child believes that women and children must be placed at the center of COVID-19 recovery plans. They have launched a new “Five Questions” feature to feature partners who are working to make sure that no one from these vulnerable groups is left behind
Enriching the drug discovery pipeline with an "irresistible" compound
Dr Thierry Diagana, Dr Brice Campo
MMV’s Project of the Year 2019 is awarded to a discovery team led by Dr Thierry Diagana at the Novartis Institute for Tropical Diseases (NITD) and Dr Brice Campo, Senior Director, Drug Discovery at MMV, for delivering a promising new and ‘irresistible’ preclinical candidate, INE963. Dr Diagana and Dr Campo from the INE963 discovery collaboration team tell us more.
EDCTP interviews MMV’s Chief Scientific Officer
Tim Wells highlights important elements of the PAMAfrica project
Next-generation researchers: in malaria and beyond
Next-generation researchers in malaria and other neglected diseases discuss their work and aspirations.
Reflections of the MMV Board: Successes, challenges and aspirations
Robert Newman, David Bowen, Winston E. Gutteridge, Per Wold-Olsen, Yuli Ismartono, Konji Sebati, Gabriel Jaramillo, David Brandling-Bennett, Dennis Schmatz, Dominique Limet, Wendy R. Sanhai, Michael Ferguson, Elizabeth Linder
In celebration of MMV's 20th anniversary this month, Board members reflect on past successes, challenges and future aspirations for the role of MMV within the evolving malaria landscape.
MMV on the ground: stories from the field and the lab
Stephan Duparc, André-Marie Tchouatieu, Jaya Banerji, James Duffy
Four MMV staff discuss some of their most memorable experiences.
From “enthusiastic amateur” to indispensable contributor: 20 years of service to malaria drug discovery
Sir Simon Campbell, Former SVP for WW Discovery, Pfizer, MMV ESAC member
Sir Simon Campbell tells us about what it was like to take part in MMV’s beginnings, how ESAC has evolved over the past 20 years and how he sees the organization developing over the next decades.
MAM initiative: increasing access to rectal artesunate in rural communities
Dr Elizabeth Chizema
Dr Elizabeth Chizema explains the approaches taken by Zambia and the role of MAM as it works towards eliminating malaria.
Stimulating research into neglected and pandemic diseases
Dr Kirandeep Samby, Medicinal Chemist, MMV Consultant
Dr Kirandeep Samby talks about MMV's latest open access initiative.
The evolution of drug discovery
Dr Jeremy Burrows, Head of Drug Discovery, MMV
Dr Jeremy Burrows reflects on recent progress and partnerships in drug discovery at MMV.
Taking aim at malaria: a target-based approach to drug design
Dr Beatriz Baragaña, Prof. Ian Gilbert, Paul Willis, Prof. Kevin Read, Delphine Baud
Five members of the 2018 Project of the Year team discuss a target-based approach to drug design.
Keeping an eye on relapsing malaria
Dr Kamini Mendis, Independent Consultant in Malaria and Tropical Medicine, Sri Lanka
Dr Kamini Mendis, Independent Consultant in Malaria and Tropical Medicine, Sri Lanka, explains the successes and challenges on the road to eliminating malaria in Southeast Asia as well as the role of new tools in revitalizing efforts.
MMV women in R&D
Anna Thomas, Nicole Andenmatten, Fiona Macintyre, Nada Abla Geiser, Helen Demarest, Isabelle Borghini-Fuhrer, Alice Neequaye, Wiweka Kaszubska, Mélanie Rouiller, Antonia Wolff, Cristina Donini, Aline Fuchs
This month, in celebration of International Women’s Day, MMV women in R&D discuss childhood heroines, progress that has been made for women in science over the course of their careers and inspiring young women to follow a science path.
20 years of drug discovery
Dr Didier Leroy, Senior Director, Drug Discovery, MMV & Dr Brice Campo, Director, Drug Discovery, MMV
As our 20th anniversary nears, two MMV drug discovery scientists discuss advancements that have been made and the challenges that lie ahead in the discovery of antimalarial medicines.
Overcoming challenges to tackle malaria relapse
Prof. Alejandro Llanos-Cuentas, Universidad Peruana Cayetano Heredia, Lima, Peru
Prof. Llanos, one of the principal investigators for the Phase III trials of tafenoquine in Peru, explains the challenges in treating malaria and how tafenoquine could help.
New tools to identify optimal drug combinations
Dr Nicole Andenmatten, Project Manager, Translational Science, MMV
MMV and partners have developed and implemented a series of platforms to gather data to feed into a tool that enables everycompound pair to be compared in a similar manner. This allows unbiased prioritization of optimal drug combinations for further research. Dr Nicole Andenmatten explains how new tools are being employed to determine which drug combinations should progress further.
New molecule to protect vulnerable and migratory populations
Dr Alfred Tonelli, Head of External Innovation, Johnson and Johnson Global Public Health
MMV is working with Janssen Pharmaceuticals to develop long-acting injectable chemoprotective medicines that could be administered monthly or even less frequently. Dr Alfred Tonelli talks about chemoprotection and the development plan for P218.
Novel assays to identify anti-relapse compounds
Dr Steve Maher, Assistant Research Scientist, Center for Tropical and Emerging Global Diseases, University of Georgia, USA
New treatments for malaria relapse prevention without the G6PD liability are urgently needed. The development and use of novel assays to identify next-generation anti-relapse compounds is ongoing at several sites. Dr Steve Maher tells us about his work on a new high throughput assay.
Preventing malaria relapse with a single-dose treatment
Anna Thomas, Senior Director, Regulatory Lead, MMV and Robert Stocken, Director and Global, Regulatory Lead, GSK
Tafenoquine is a potential new single-dose cure to prevent the relapse of P. vivax malaria. Anna and Robert discuss the potential impact of tafenoquine in the management of P. vivax malaria, and explain the next steps for achieving regulatory approval and country registration.
M5717 (formerly DDD498)
Dr Jutta Reinhard-Rupp, Head of Merck Global Health Institute, Merck Group
M5717 is a compound with a novel mechanism of action, targeting the protein-making machinery of the malaria parasite. Dr Jutta Reinhard-Rupp talks about the vision of the Merck Global Health Institute, its partnership with MMV, and how volunteer infection studies (VIS) are contributing to the clinical evaluation of M5717.
Dr Jörg Möhrle, Vice President, Head of Translational Medicine, MMV
DSM265 is one of the new generation of novel antimalarials and has the potential to both treat patients and protect healthy people with a reduced dosing schedule. Dr Jörg Möhrle talks about the potential of DSM265 and its role in validating the sporozoite volunteer infection study platform.
Dr Charles Wells, Head of Development/Associate Vice President, Infectious Diseases Therapeutic Area, Sanofi, USA
The combination of artefenomel and ferroquine has the potential to become the first of a new generation of antimalarials not based on artemisinin and therefore an important tool in the context of drug resistance. MMV and Sanofi are currently conducting a phase IIb programme to determine the safety and efficacy of the combination as a single-dose cure. Dr Charles Wells talks about the potential of artefenomel/FQ as a next-generation drug combination.
David Hughes, Senior Global Program Head, Anti-infectives, Novartis Pharma
KAF156 is the first compound to progress into clinical development from the novel imidazolopiperazine class of antimalarial molecules. A key strength of the drug is its potential to both treat and prevent malaria, including resistant strains. David Hughes talks about the benefits of the KAF156/lumefantrine combination and how it could help malaria-endemic countries move towards malaria elimination.
Improving malaria treatment during pregnancy
Dr Rukhsana Ahmed, Postdoctoral Research Associate in Clinical Epidemiology, Liverpool School of Tropical Medicine, UK
MMV is supporting a study in Indonesia to gather significantly more data – retrospectively and prospectively – on the safety of DHA-PQP during all trimesters of pregnancy. Dr Rukhsana Ahmed talks about her experience of working on this important research.
Protecting children when they are most vulnerable
Dr Djermakoye Hadiza Jackou, Coordinator of the National Malaria Control Programme in Niger
Seasonal malaria chemoprevention (SMC) was recommended by the World Health Organization (WHO) in 2012 to protect children from being infected in areas of high seasonal malaria in the Sahel region of Africa. Dr Djermakoye Hadiza Jackou talks about the progress and challenges of SMC roll-out in Niger.
Treatment options for children with uncomplicated malaria
Dr Ghyslain Mombo-Ngoma, Head of Clinical Operations Department, CEREMEL, Gabon
MMV works with partners to generate and disseminate post approval evidence of the safety and efficacy of high quality medicines in the real world, especially in children. Dr Ghyslain Mombo-Ngoma explains the potential of Pyramax® granules in benefiting young children.
Advancing access to life-saving severe malaria medicines
Caroline Barber, CEO of Transaid
In July 2017, MMV joined forces with international development organization Transaid, in collaboration with the National Malaria Elimination Centre (NMEC) of Zambia on a project known as MAMaZ Against Malaria (MAM) to improve severe malaria case management. Caroline Barber tells us more about the MAM project and the role of rectal artesunate.
Using biology to help guide the search for new molecules
Dr Didier Leroy, Senior Director, Drug Discovery, MMV and Dr Alain Pellet, Pharmaceutical Chemistry Team Leader, Sanofi
The discovery team led by Dr Alain Pellet at Sanofi and Dr Didier Leroy at MMV receives MMV’s 2017 Project of the Year award for the identification and development of SAR441121. Alain and Didier talk about the partnership and the exciting features of this antimalarial compound.